United States of America
The Ryan Haight Act Known as
Online Pharmacy Consumer Protection Act of 2008
Sec. 2. Requirement of a valid prescription for
controlled substances dispensed by means of the Internet.
SUMMARY: The Ryan Haight Online Pharmacy Consumer Protection Act,
which was enacted on October 15, 2008,amended the Controlled Substances Act and Controlled Substances Import and Export Act by adding several new provisions to prevent the illegal distribution and dispensing of controlled substances by means of the Internet.
DEA Warning–Buying drugs online may be illegal and dangerous!
Federal law prohibits buying controlled substances such as narcotic pain relievers (e.g., OxyContin®, Vicodin®), sedatives (e.g., Valium®, Xanax®, Ambien®), stimulants (e.g., phentermine, phendimetrazine, Adderall®, Ritalin®) and anabolic steroids (e.g., Winstrol®, Equipoise®) without a valid prescription from your doctor.
This means there must be a real doctor-patient relationship, which by most state laws requires a physical examination. Prescriptions written by “cyber doctors” relying on online questionnaires are not legitimate under the law.
FDA Issued Warning
Address lookup
canonical name canadadrugs.com
aliases
addresses 108.162.204.105
108.162.203.105
Domain Whois record
Queried whois.internic.net with “dom canadadrugs.com”…
Domain Name: CANADADRUGS.COM
Registrar: FABULOUS.COM PTY LTD.
Whois Server: whois.fabulous.com
Referral URL: http://www.fabulous.com
Name Server: COCO.NS.CLOUDFLARE.COM
Name Server: RAY.NS.CLOUDFLARE.COM
Status: clientTransferProhibited
Updated Date: 31-may-2012
Creation Date: 06-aug-1999
Expiration Date: 06-aug-2020
>>> Last update of whois database: Sun, 15 Jul 2012 04:44:13 UTC <<<
Queried whois.fabulous.com with “canadadrugs.com”…
Domain canadadrugs.com:
Canada Drugs IT
24 Terracon Place
Winnipeg, Manitoba R2J4G7 CA
Administrative contact:
Technical contact:
Billing contact:
Canada Drugs IT
Canada Drugs IT
domains@canadadrugsit.com
24 Terracon Place
Winnipeg, Manitoba R2J4G7 CA
Phone: +1.2046545197
Fax: +1.2046617051
Record dates:
Record created on: 1999-08-06 05:42:38 UTC
Record modified on: 2012-07-02 21:51:01 UTC
Record expires on: 2020-08-06 UTC
Nameservers:
coco.ns.cloudflare.com
ray.ns.cloudflare.com
Note: Automated collection of data from this database is strictly prohibited.
Network Whois record
Queried whois.arin.net with “n 108.162.204.105″…
NetRange: 108.162.192.0 – 108.162.255.255
CIDR: 108.162.192.0/18
OriginAS: AS13335
NetName: CLOUDFLARENET
NetHandle: NET-108-162-192-0-1
Parent: NET-108-0-0-0-0
NetType: Direct Assignment
Comment: http://www.cloudflare.com
RegDate: 2011-10-28
Updated: 2012-03-02
Ref: http://whois.arin.net/rest/net/NET-108-162-192-0-1
OrgName: CloudFlare, Inc.
OrgId: CLOUD14
Address: 665 Third Street #207
City: San Francisco
StateProv: CA
PostalCode: 94107
Country: US
RegDate: 2010-07-09
Updated: 2011-11-03
Comment: http://www.cloudflare.com/
Ref: http://whois.arin.net/rest/org/CLOUD14
OrgAbuseHandle: ABUSE2916-ARIN
OrgAbuseName: Abuse
OrgAbusePhone: +1-650-319-8930
OrgAbuseEmail: abuse@cloudflare.com
OrgAbuseRef: http://whois.arin.net/rest/poc/ABUSE2916-ARIN
OrgNOCHandle: NOC11962-ARIN
OrgNOCName: NOC
OrgNOCPhone: +1-650-319-8930
OrgNOCEmail: noc@cloudflare.com
OrgNOCRef: http://whois.arin.net/rest/poc/NOC11962-ARIN
OrgTechHandle: ADMIN2521-ARIN
OrgTechName: Admin
OrgTechPhone: +1-650-319-8930
OrgTechEmail: admin@cloudflare.com
OrgTechRef: http://whois.arin.net/rest/poc/ADMIN2521-ARIN
RNOCHandle: NOC11962-ARIN
RNOCName: NOC
RNOCPhone: +1-650-319-8930
RNOCEmail: noc@cloudflare.com
RNOCRef: http://whois.arin.net/rest/poc/NOC11962-ARIN
RAbuseHandle: ABUSE2916-ARIN
RAbuseName: Abuse
RAbusePhone: +1-650-319-8930
RAbuseEmail: abuse@cloudflare.com
RAbuseRef: http://whois.arin.net/rest/poc/ABUSE2916-ARIN
RTechHandle: ADMIN2521-ARIN
RTechName: Admin
RTechPhone: +1-650-319-8930
RTechEmail: admin@cloudflare.com
RTechRef: http://whois.arin.net/rest/poc/ADMIN2521-ARIN
DNS records
DNS query for 105.204.162.108.in-addr.arpa returned an error from the server: NameError
name class type data time to live
canadadrugs.com IN SOA
server: coco.ns.cloudflare.com
email: dns@cloudflare.com
serial: 2012070816
refresh: 10000
retry: 2400
expire: 604800
minimum ttl: 600
86400s (1.00:00:00)
canadadrugs.com IN A 108.162.204.105 300s (00:05:00)
canadadrugs.com IN A 108.162.203.105 300s (00:05:00)
canadadrugs.com IN MX
preference: 10
exchange: canadadrugs.com.s7b1.psmtp.com
300s (00:05:00)
canadadrugs.com IN MX
preference: 5
exchange: canadadrugs.com.s7a2.psmtp.com
300s (00:05:00)
canadadrugs.com IN MX
preference: 0
exchange: canadadrugs.com.s7a1.psmtp.com
300s (00:05:00)
canadadrugs.com IN MX
preference: 15
exchange: canadadrugs.com.s7b2.psmtp.com
300s (00:05:00)
canadadrugs.com IN NS coco.ns.cloudflare.com 86400s (1.00:00:00)
canadadrugs.com IN NS ray.ns.cloudflare.com 86400s (1.00:00:00)
canadadrugs.com IN TXT v=spf1 mx ptr ip4:62.149.35.27 ip4:66.225.137.229 ip4:64.18.0.0/20 mx:canadadrugs.com.s7a1.psmtp.com mx:canadadrugs.com.s7a2.psmtp.com mx:canadadrugs.com.s7b1.psmtp.com mx:canadadrugs.com.s7b2.psmtp.com ~all 300s (00:05:00)
— end —
scamFRAUDalert®Pharmacies Checker 
Canadadrugs 9/21/12
Department of Health and Human Services logoDepartment of Health and Human Services
Public Health Service
Food and Drug Administration
Silver Spring, MD 20993-0002
TO: troy@harwoodjones.com
FROM: Food and Drug Administration Internet Pharmacy Task Force
RE: Internet Marketing of Unapproved and Misbranded Drugs
DATE: September 21, 2012
WARNING LETTER
This revised warning letter supersedes the warning letter sent to you on September 18, 2012. The warning letter sent to you on September 18, 2012, is withdrawn.
The United States Food and Drug Administration (FDA) recently reviewed your websites (listed in the table located at the bottom of this letter and in the attachment) and has determined that your websites offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved and misbranded new drugs for sale in violation of sections 301(a), 301(d), 502(a), 502(f), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 352(a), 352(f), 355(a)]. We request that you immediately cease marketing violative drug products to United States consumers.
Unapproved New Drugs
Certain products you offer for sale through your websites are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These products are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act [21 U.S.C. §§ 355(a) and 331(d)].
As a few examples, your firm offers for sale through your websites products such as “Viagra” and “Levitra,” which are the proprietary names of FDA-approved drugs well-known for their intended use(s) to treat disease, and as such are subject to section 505 of the FD&C Act [21 U.S.C. § 355]. However, your websites offer “Viagra” and “Levitra” that are manufactured by manufacturers that are not the subject of the FDA-approved applications, and accordingly, no approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for the products your firm offers for sale. The drugs your firm offers for sale without approved applications are in violation of section 505 of the FD&C Act [21 U.S.C. § 355].
In addition to the above-mentioned drug products offered for sale through your websites, your firm offers unapproved and misbranded domperidone. In 2004, amid safety concerns, FDA issued a consumer alert for breastfeeding women warning against the use of domperidone for increased milk production. Such reported safety concerns included cardiac arrhythmias, cardiac arrest, and sudden death. FDA concurrently issued warning letters to pharmacies that were compounding products containing Domperidone and to firms that supplied domperidone for use in compounding. Domperidone is not approved for any human use in the U.S., and it is currently subject to an import alert (61-07) instructing FDA personnel to detain and refuse entry of any shipments of this drug offered for importation to the US.
Misbranded Drugs
Because the above mentioned drugs are intended for conditions that are not amenable to self-diagnosisand treatment by individuals who are not medical practitioners, adequate directions cannot be written for them so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses, causing them to be misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]. Because some of your products lack required approved applications, they are not exempt under 21 C.F.R. § 201.115 from the requirements of section 502(f)(1) of the FD&C Act.
Furthermore, your websites offer unapproved Accutane (isotretinoin) for sale. FDA approved the new drug application (NDA) for Accutane in 1982, but withdrew the approval via a Federal Register Notice effective November 22, 2010. The Accutane product offered for sale on your websites is unapproved within the meaning of section 505(a) of the FD&C Act [21 U.S.C. § 355(a)] in that this is a new drug without an approved application. The introduction or delivery for introduction into interstate commerce of unapproved drug products violates section 301 of the FD&C Act [21 U.S.C. § 331]. Moreover, your websites offer for sale misbranded drugs containing isotretinoin. Although isotertinoin is legally marketed under approved abbreviated new drug applications (ANDAs), FDA-approved drugs containing isotretinoin are available in the United States only under specially created safety controls. If these products are not taken under the close supervision of a healthcare professional and pharmacist, they can be a potentially dangerous prescription drug. Because isotretinoin has serious risks, patients, their doctors and pharmacists are required by FDA to register with the iPLEDGE program in order to receive this medication, among other requirements. These safety controls are bypassed when this drug is purchased from foreign sources or over the Internet, placing patients who use this drug at risk. To offer isotretinoin for sale without the above-mentioned safety controls misbrands the product as it is false and misleading to the consumer and adequate warnings against use are not provided per sections 502(a) of the FD&C Act [21 U.S.C. § 352(a)] and 502(f)(2) of the FD&C Act [21 U.S.C. § 352(f)(2)], respectively.
FDA is taking this action against your firm because of the inherent risk in buying unapproved and misbranded new drugs. Unapproved new drugs from unregulated sources do not have the same assurance of safety and effectiveness as those drugs subject to FDA oversight, and such drugs have been found to be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.
This letter is not intended to identify all of the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products marketed by your firm are in compliance with the FD&C Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in regulatory action, including but not limited to, seizure and/or injunction without further notice.
Please notify this office in writing within 10 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 10 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response and any other inquiries concerning this letter should be sent to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.
Sincerely,
/S/
Thomas Christl
Director
Office of Drug Security, Integrity, and Recalls
Office of Compliance
Center for Drug Evaluation and Research
cc:
24 Terracon Place
Winnipeg, Manitoba, Canada, R2J 4G7
14 Terracon Place
Winnipeg, Manitoba, Canada R2J 4G7
Email: troy@harwoodjones.com